TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00547625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
Study: NCT00159419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Study: NCT01459198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MEDI ΔM2-2 vaccine
Description: Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MEDI ΔM2-2 vaccine
Description: Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
Study: NCT02226094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DWT device dose A
Description: Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellex Tango SLT machine
Description: Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
Study: NCT01459198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MEDI ΔM2-2 vaccine
Description: Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MEDI ΔM2-2 vaccine
Description: Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Given intranasally once at a baseline study visit

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Given intranasally once at a baseline study visit

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Given intranasally once at a baseline study visit
Study: NCT02365909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine
Description: This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
Study: NCT02226094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DWT device dose B
Description: Same as DWT device dose A except 20 second spot treatments.
Study: NCT02365909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
Study: NCT03468296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection 2mg
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept Injection 2mg
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
Study: NCT04428905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan
Description: Receive personalized care plan/resource manual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Participate in telehealth sessions
Study: NCT00559637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
Study: NCT00959439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
Study: NCT01642563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: One dose of pathogen reduced platelets

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: One dose of standard platelets
Study: NCT01710124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Study: NCT01744964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: 1.5 mg Apomorphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apomorphine
Description: 1.5 mg Apomorphine
Study: NCT01958060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1034020
Description: intravenous part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1034020
Description: intravenous part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1034020
Description: intravenous part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1034020
Description: intravenous part
Study: NCT02771028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques
Study: NCT00880334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given intravenously on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given intravenously on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: taken orally once a day, every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Taken orally once a day every day
Study: NCT00298987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, Twice daily, 2 months.
Study: NCT03191838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual Distraction
Description: The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
Study: NCT02226094

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DWT sham
Description: Same as DWT device dose A except device not applied to ocular surface.
Study: NCT01966809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin photodynamic therapy.
Description: The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery.
Study: NCT00313508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells (DC)
Description: Given intranodally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells (DC)
Description: Given intranodally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Lymphocyte Infusion (ALI)
Description: Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Lymphocyte Infusion (ALI)
Description: Infusion
Study: NCT03454282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD
Description: The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
Study: NCT03816436

Intervention type: OTHER
Intervention: Follow- up (FU) assessment
Description: Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
Study: NCT02710214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Selective Estrogen Complex
Description: Once-daily dosing of Duavee for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily dosing of placebo for 8 weeks
Study: NCT00179673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
Study: NCT04304274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block-ropivacaine
Description: Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Paravertebral block-saline
Description: Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patient controlled analgesia with morphine
Description: Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: patient controlled analgesia with morphine
Description: Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
Study: NCT02959983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eluxadoline
Description: Eluxadoline 100 mg oral tablets BID with food.
Study: NCT00712114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
Study: NCT01971476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volasertib
Description: intravenous administration on day 1of a treatment course
Study: NCT03742960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Restriction
Description: Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
Study: NCT03988387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder and Resource Transfer (RRT)
Description: Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]
Description: All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]
Description: All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
Study: NCT02959983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching eluxadoline oral tablets BID with food.
Study: NCT03860610

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle strength test
Description: Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle strength test
Description: Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
Study: NCT04220528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/Tiggio
Description: Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2).
Study: NCT02280538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Articular Hyaluronic Acid

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00964314

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: music
Description: Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done.
Study: NCT02000934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet
Study: NCT00621959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine dihydrochloride
Description: 5mg daily (oral tablet) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg (matching oral tablet)for 14 days
Study: NCT00590135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin (Lipitor)
Description: atorvastatin 40 mg by mouth once daily
Study: NCT04250922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMZ
Description: TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: RT
Description: During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
Study: NCT00646074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Talk
Description: 6 conversational sessions
Study: NCT02967432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Topical Ointment
Description: Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
Study: NCT00964314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done.
Study: NCT02967432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum Jelly
Description: Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
Study: NCT00921401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Feedback
Description: All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Feedback
Description: All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
Study: NCT01449019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exendin(9-39)amide
Description: intravenous infusion of exendin(9-39)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intravenous infusion of saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duodenal meal
Description: duodenal perfusion of a meal
Study: NCT00260689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (horse)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study: NCT01449019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duodenal saline
Description: duodenal perfusion of saline
Study: NCT04174638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Education Based on Watson's Theory of Human Caring
Description: The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
Study: NCT03924024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst treatment
Description: All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator.
Study: NCT03403504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Tamper Resistant
Description: Orally administered Oxycodone Tamper Resistant 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXYCONTIN®
Description: Orally administered OXYCONTIN® Tablet 10 mg